DB-1305/BNT325 is named as a drug or biological intervention in 2 clinical trials in our USA and China trial registers, 1 of which is recruiting. The lead sponsor is DualityBio Inc.. Registered phases: Phase 2 and Phase 1/2. Conditions studied include Solid Tumors; Advanced Solid Tumor.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06953089 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors (ClinicalTrials.gov ↗) Solid Tumors |
Phase 2 | Recruiting |
| NCT05438329 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Solid Tumors | 1 |
| Advanced Solid Tumor | 1 |
| Lead sponsor | Trials |
|---|---|
| DualityBio Inc. | 2 |
| Register | DB-1305/BNT325 trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how DB-1305/BNT325 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists DB-1305/BNT325 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.